Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bristol-Myers Squibb

47.92
-0.5100-1.05%
Post-market: 47.960.0400+0.08%19:55 EDT
Volume:11.61M
Turnover:558.63M
Market Cap:97.54B
PE:19.28
High:49.11
Open:48.84
Low:47.72
Close:48.43
52wk High:63.33
52wk Low:42.96
Shares:2.04B
Float Shares:2.03B
Volume Ratio:1.24
T/O Rate:0.57%
Dividend:2.46
Dividend Rate:5.13%
EPS(TTM):2.49
EPS(LYR):-4.4144
ROE:29.32%
ROA:8.34%
PB:5.59
PE(LYR):-10.86

Loading ...

Press Release: HUTCHMED Announces Appointment of Acting Chief Executive Officer

Dow Jones
·
3 hours ago

Assessing Bristol-Myers Squibb (BMY) Valuation After Recent Share Price Pullback

Simply Wall St.
·
Aug 23

Bristol Myers Squibb Co. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
Aug 23

Bristol-Myers Squibb’s New Lung Cancer Study: Potential Market Impact

TIPRANKS
·
Aug 23

Bristol-Myers Squibb’s Promising Phase 3 Alzheimer’s Study: A Potential Game-Changer?

TIPRANKS
·
Aug 23

ServiceNow, Live Nation Entertainment And A Health Care Stock: CNBC's 'Final Trades'

Benzinga
·
Aug 22

Bristol-Myers Squibb’s TRIDENT-3 Trial: A Game Changer in Lung Cancer Treatment?

TIPRANKS
·
Aug 21

Agilent Technologies' MMR IHC Panel Receives FDA Approval as Companion Diagnostic for Colorectal Cancer Treatment

Reuters
·
Aug 20

Bristol-Myers Squibb’s ELEMENT-MDS Trial: A New Hope for Anemia Treatment in MDS Patients

TIPRANKS
·
Aug 20

Inhibikase Therapeutics Appoints Timothy Pigot as Chief Commercial and Strategy Officer to Bolster Leadership Team

Reuters
·
Aug 19

Bristol-Myers Squibb's Izalontamab Brengitecan Granted Breakthrough Therapy Designation by FDA for Advanced EGFR-Mutated Lung Cancer

Reuters
·
Aug 18

Izalontamab Brengitecan (Egfrxher3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients With Previously Treated Advanced Egfr-Mutated Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Aug 18

Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS

Benzinga_recent_news
·
Aug 17

Big Pharma Has a New Vision for Selling Drugs. It's Going to the Mattresses. -- Barrons.com

Dow Jones
·
Aug 15

Bristol-Myers Squibb’s KarXT Study: Potential Game-Changer for Bipolar-I Disorder

TIPRANKS
·
Aug 15

Bristol Myers Squibb Co. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Aug 14

Cantor Fitzgerald Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)

TIPRANKS
·
Aug 14

Bristol-Myers Squibb’s Promising Study on Advanced Solid Tumors: A Market Perspective

TIPRANKS
·
Aug 14

Bloomsbury Publishing Corrects Director Shareholding Details Post-Share Plan Vesting

TIPRANKS
·
Aug 13

Cantor Fitzgerald Adjusts Price Target on Bristol-Myers Squibb to $45 From $55, Maintains Neutral Rating

MT Newswires Live
·
Aug 13